Korea’s Celltrion has confirmed a European filing for its CT-P16 proposed biosimilar version of Avastin (bevacizumab), following the firm’s recent submissions in its domestic market and the US.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?